Another partnership - Haematological Malignancies
https://xencor.com/pipeline/
Xencor - current market cap USD $2.072B
https://www.businesswire.com/news/h...reatment-of-Patients-With-B-Cell-Malignancies
Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies
-- Second agreement with Janssen on bispecific antibodies directed toward the CD28 co-stimulatory receptor on T cells --
Xencor to receive $100 million upfront payment and $25 million equity investment and is eligible for a mid-teen to low-twenties percent royalty for plamotamab and potential milestone payments up to $1.188 billion
Another partnership - Haematological Malignancies...
-
- There are more pages in this discussion • 1,944 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
0.000(0.00%) |
Mkt cap ! $281.1M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1678 | $1.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.61 | 100 | 1 |
View Market Depth
| Last trade - 09.59am 29/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |
Day chart unavailable